Journal article

A review of β-amyloid neuroimaging in Alzheimer's disease

PA Adlard, BA Tran, DI Finkelstein, PM Desmond, LA Johnston, AI Bush, GF Egan

Frontiers in Neuroscience | Frontiers Research Foundation | Published : 2014

Abstract

Alzheimer's disease (AD) is the most common cause of dementia worldwide. As advancing age is the greatest risk factor for developing AD, the number of those afflicted is expected to increase markedly with the aging of the world's population. The inability to definitively diagnose AD until autopsy remains an impediment to establishing effective targeted treatments. Neuroimaging has enabled in vivo visualization of pathological changes in the brain associated with the disease, providing a greater understanding of its pathophysiological development and progression. However, neuroimaging biomarkers do not yet offer clear advantages over current clinical diagnostic criteria for them to be accepte..

View full abstract

Grants

Funding Acknowledgements

Paul A. Adlard is supported by an Australian Research Council (ARC) Future Fellowship, Gary E Egan is supported by a National Health and Medical Research Council Principal Researcher Fellowship, Ashley I. Bush is supported by a National Health and Medical Research Council Australia Fellowship. In addition, the Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the Victorian Government and in particular the funding from the Operational Infrastructure Support Grant.